Inhibitors of immuno-oncology target HPK1 – a patent review (2016 to 2020)
Author:
Affiliation:
1. Medicinal Chemistry, Charles River, Chesterford Park Research Park, Saffron Walden, United Kingdom
2. Medicinal Chemistry, Nimbus Therapeutics, Cambridge, MA, USA
Publisher
Informa UK Limited
Subject
Drug Discovery,Pharmacology,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/13543776.2021.1924671
Reference84 articles.
1. Cancer immunoediting from immune surveillance to immune escape
2. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
3. Oncology Meets Immunology: The Cancer-Immunity Cycle
4. Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
5. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Tetrahydroisoquinolines – an updated patent review for cancer treatment (2016 – present);Expert Opinion on Therapeutic Patents;2024-08-19
2. Design, synthesis, and biological evaluation of 2,4-diaminopyrimidine derivatives as potent Hematopoietic Progenitor Kinase 1 (HPK1) inhibitors;Bioorganic Chemistry;2024-07
3. Macrocyclization strategy for improving candidate profiles in medicinal chemistry;European Journal of Medicinal Chemistry;2024-06
4. Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress;Expert Opinion on Therapeutic Targets;2024-04-02
5. Discovery of 5-aminopyrido[2,3-d]pyrimidin-7(8H)-one derivatives as new hematopoietic progenitor kinase 1 (HPK1) inhibitors;European Journal of Medicinal Chemistry;2024-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3